Monte Rosa Therapeutics (GLUE) Restructuring Costs (2024 - 2026)

Monte Rosa Therapeutics' Restructuring Costs history runs 3 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• In Q1 2026, Restructuring Costs rose 22.89% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $35.7 million (up 15.13% YoY), while the FY2025 annual figure was $33.9 million, up 14.3% from the prior year.
• Restructuring Costs was $10.1 million for Q1 2026 at Monte Rosa Therapeutics, up from $9.2 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $10.1 million in Q1 2026 to a low of $6.8 million in Q1 2024.
• Historically, Restructuring Costs has averaged $8.2 million across 3 years, with a median of $7.8 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Restructuring Costs climbed 2.99% in 2025, then grew 22.89% in 2026.
• A 3-year view of Restructuring Costs shows it stood at $7.7 million in 2024, then increased by 18.95% to $9.2 million in 2025, then climbed by 9.74% to $10.1 million in 2026.
• The last three Restructuring Costs figures came in at $10.1 million (Q1 2026), $9.2 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.